CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.3200
0.00 (0.00%)
At close: Dec 5, 2025
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,731,231
Market Cap
403.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Zomedica | 152 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| Nuo Therapeutics | 9 |
CytoDyn News
- 5 days ago - CytoDyn Announces Resolution of Class Action Lawsuit - GlobeNewsWire
- 12 days ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 weeks ago - CytoDyn (CYDY) Secures $30 Million Funding Commitment from Yorkville - GuruFocus
- 4 weeks ago - CytoDyn (CYDY) Secures $30M Funding for Cancer Drug Development - GuruFocus
- 4 weeks ago - CytoDyn secures $30M equity funding commitment - Seeking Alpha
- 4 weeks ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire
- 6 weeks ago - Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - CytoDyn to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire